Ongoing Projects

HOME > R&D Pipeline > Current status > Ongoing Projects

KDDF-201709-57 Development of new mechanism based therapeutic antibodies in non-small cell lung cancer(Oncology, Protein) [2019-02-22]

PRINT
Ongoing Project
Section Lead
Generation
Lead
Optimization
Preclinical Phase I Phase II Phase III

Development and Market Objectives

Identification of new mechanism based first-in-class therapeutic antibody candidate targeting CMG for the treatment of Non-Small Cell Lung cancer.

Unmet Medical Need & Target Patients

1) Indication: Non-Small Cell Lung Cancer

2) Unmet Medical Needs

- Chemo-agents are Drugs commonly used for the treatment of Non-small cell lung cancers but Resistance to cancer chemotherapeutic treatment is a common phenomenon, especially in progressive disease. Targeted therapies such as EGFR or ALK inhibitors have limitations due to low response rate and drug resistance.

- Recent advances in immune checkpoint inhibitors have limited application to autoimmune disease (Type I Diabetes, Colitis, Hepatitis, Interstitial lung disease, etc.), immune related adverse events.

-Due to the lack of predictive biomarker and pharmacodynamic biomarker for immunotherapeutic drugs, controversy exists about response rate and efficacy. New mechanism based therapeutics is urgently needed.

Status

- Identification of candidates through lead optimization

- In vitro/ in vivo efficacy tests of the antitumor antibody

- Immunotherapeutic efficacy test and analysis for cytokines in syngeneic mouse model

- Verification of new target and analysis of expression rates in patient tissue

- MOA analysis and identification and verification of biomarker for antitumor antibody

Intellectual Property

-Biomarker patent:  1 patent registration at South Korea, Patent application at 4 countries (United States, China, Europe, Japan)

-Therapeutic antibody patent: On going

 

Competitive Advantages

 Antitumor antibody with a new target, good efficacy, no competing drug and a predictive biomarker can be differentiated from other competing drugs in the global market.

Contact & Company Overview

Related Project

Related Project
list
Update to 2013 © KOREA DRUG DEVELOPMENT FUND. ALL RIGHTS RESERVED. QR Code